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Purpose. People living with HIV have higher rates of malignan-
cies than the general population in the era of active antiretrovi-
ral therapy (ART). Genotoxic effects of HIV infection and/or ART 
that can induce neoplastic development are not yet well known. 
A prospective cohort study to investigate DNA damage measured 
through the micronuclei (MN) frequency in HIV-patients has been 
performed. 
Methods. Peripheral blood mononuclear cells (PBMC) were 
isolated from 52 HIV-patients treated with ART and 55 healthy 
controls. 
Results. By the comparison of MN frequency, a significant differ-
ence between HIV-patients (15.5 ± 9.8) and controls (6.0 ± 3.6) 
(p  <  0.001) has been revealed. In univariate linear regression 
analysis, HCV infection (r = 0.31; p < 0.001), HIV-RNA (r = 0.29; 
p < 0.03) and duration of infection (r = – 0.16; p < 0.25) were 
associated with MN frequency; while only viral load (VL) sig-
nificantly correlates (r = 0.29; p < 0.05) in a multiple regression 
model. 
Conclusions. The association of VL with MN frequency supports 
a genotoxic effect of HIV infection.
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Introduction
The Human Immunodeficiency Virus (HIV) infects 
cells of the host immune system, which is gradually de-
stroyed; monocytes/macrophages and CD4+ T lympho-
cytes (CD4+) are the main targets of infection. Active 
viral replication leads to a progressive decline of CD4+ 
with gradual immunosuppression of host and increased 
susceptibility to opportunistic infections [1].
In HIV patients, CD4+ count and HIV-RNA (viral load, 
VL) are the markers of clinical progression used to man-
age and to monitor the infection. A large number of 
HIV patients are also coinfected with hepatitis C virus 
(HCV) [2, 3]; the co-infection is associated with an in-
creased risk of progression to AIDS [4] and poor CD4 
T cell recovery even after years of active antiretroviral 
therapy (ART) [5].
The introduction of ART in 1996 has significantly im-
proved immune response and life expectancy of HIV 
infected individuals with consequent significant decline 
in the incidence of virus-related AIDS-defining malig-
nancies (ADMs), as Kaposi’s sarcoma, non-Hodgkin 
lymphoma and invasive cervical cancer [6], representing 
an index of clinically remarkable immunosuppression. 
On the other hand, several non-AIDS defining malig-
nancies (NADMs), such as hepatocellular carcinoma 
(HCC), Hodgkin’s lymphoma (HL), anal cancer, lung 
cancer, colorectal cancer (CRC), gastrointestinal cancer 
(GI), breast cancer, cardiovascular diseases, liver dis-
eases, kidney and neurodegenerative diseases have been 
observed [7-9].
Nevertheless, long-term use of ART exposes the patients 
to an increased risk of metabolic disorders and oxidative 
stress (OS), all factors that can contribute to the onset of 
NADMs [10].
HIV patients show reduction of antioxidative activ-
ity [11], excessive production of reactive oxygen species 
(ROS) [12], reduced glutathione (GSH) levels and glu-
tathione/oxidized glutathione (GSH/GSSG) ratio, that 
seem to contribute to an increase in DNA damage [13].
The incidence of NADMs is elevated in HIV infected 
patients compared with the general population and it 
is associated with smoking use, alcohol consumption, 
overweight/obesity and oncogenic virus infection [hu-
man papillomavirus (HPV), HCV and hepatitis B virus 
(HBV)] [14].
The levels of OS markers are generally higher in HIV/
HCV co-infected than in HIV mono-infected pa-
tients  [15,  16]. To date, numerous studies have shown 
that ART triggers further the OS  [17,  18]. High inci-
dence of malignant tumours, epidemiologically associ-
ated with HIV infection, can be attributable to genotoxic 
effect of HIV that leads to double-strand breaks of chro-
mosomal DNA [19, 20]. 
Some studies report that Vpr, an accessory gene of HIV 
which induces abnormality of cell cycle causing the 
arrest in the G2-M phase, leads to a genomic instabil-
ity including formation of micronuclei (MN)  [21, 22]. 
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MN, small additional nuclei originating from chromo-
some fragments or whole chromosomes during nuclear 
division not included in the daughter nuclei in telo-
phase [23], are used as sensitive biomarker of chromo-
somal damage, genome instability and intermediate end-
point in carcinogenesis [24-26].
The aim of the study is to determine MN frequency in a 
cohort of HIV patients compared with healthy control-
group and to evaluate the relationship between demo-
graphic and clinical data and markers of DNA damage.
Methods
Study population
The study involved the enrollment of HIV-infected pa-
tients and healthy controls afferent to the Infectious 
Diseases Division of Santa Caterina Novella’s Hospital 
(Galatina, Italy) and to the Department of Immunohe-
matology and Transfusion Medicine of Vito Fazzi Hos-
pital (Lecce, Italy), respectively.
Patients with documented HIV infection treated with 
ART and older than 18 years of age were included in 
the study. Sex and age-matched, healthy HIV-uninfected 
individuals were enrolled as controls. Instead, HIV pa-
tients and healthy subjects under 18 years old, pregnant 
and/or exposed to risk factors associated with genetic 
damage (such as occupational or medical exposure to 
ionizing radiation) were excluded. 
The study was approved by the local ethics committee 
and all patients approached for the study gave written 
consent to participate (Resolution n. 811; May 3, 2012).
HIV-related clinical information (mode of transmis-
sion, duration of infection, duration of ART, HCV co-
infection and AIDS) including laboratory data (VL, CD4 
counts and CD4 nadir), were collected from HIV-infect-
ed patients at the time of study enrollment.
Relevant data including age and sex, as well as risk fac-
tors like diabetes, obesity and smoking status were avail-
able for both HIV and controls. The patients’ informa-
tion and blood samples were collected at the enrollment 
time and the MN test was immediately carried out.
Micronucleus assay
Peripheral blood samples were collected by venipunc-
ture into vacutainer blood tubes with lithium heparin 
anticoagulant. 
Cellular cultures from each subject were set up by mix-
ing 300 µl of whole blood with 4.7 ml of karyotyping 
medium. All cultures were incubated at 37°C for 44 h in 
a humidified atmosphere containing 5% CO2. For evalu-
ation of MN frequency, cells were blocked in cytokinesis 
by adding cytochalasin B after 44 h. Cell cultures were 
then harvested after 28  h and fixed for slide prepara-
tion. Therefore, the fixed cells were dropped onto clean 
iced slides, air dried and stained by the Giemsa tech-
nique [27]. 
Only binucleated lymphocytes are scored for DNA dam-
age biomarkers which include MN. For each sample, 
1000 binucleated cells were calculated blindly under 
the optical microscope for MN analysis, following the 
criteria for MN acceptance listed by Fenech  [23]. We 
have evaluated the MN frequency as the number of mi-
cronucleated-binucleated lymphocytes, containing one 
or more MN per 1000 cells.
Statistical analysis
Continuous variables were reported as the mean ± stand-
ard deviation (SD) and categorical factors as percent-
ages. The Levene’s test was used to verify the normality 
of the distribution of continuous variables. Differences 
between the means of the two continuous variables were 
evaluated by 2-tailed unpaired Student t test. Differences 
in non-continuous variables were tested by Chi-square 
test analysis or by Fisher’s exact test, as necessary.
The association between demographic and clinical vari-
ables and MN frequency was assessed by univariate 
linear regression analysis followed by multiple linear 
regression analysis per variables with p < 0.05. Statisti-
cal calculations were performed with MedCalc software, 
version 11.4.1.0. A p-value < 0.05 was considered to be 
statistically significant.
Results
52 HIV infected patients and 55 healthy controls admit-
ted at the Infectious Diseases Division of Santa Caterina 
Novella’s Hospital (Galatina, Italy) and at the Depart-
ment of Immunohematology and Transfusion Medicine 
of Vito Fazzi Hospital (Lecce, Italy) from January 2013 
to January 2015 were recruited in this study. Demo-
graphic and clinical characteristics of participants are 
illustrated in Table I.
No significant differences were observed between HIV 
patients and healthy controls in age (p  =  0.9658), sex 
(p  =  0.8727), smoking use (p  =  0.1053) and diabetes 
(p = 1.000). A highly significant difference was found 
only for HCV infection (p < 0.0001).
In the cohort of HIV patients, the average duration of 
HIV infection was of 95 months, the mean CD4 cell 
count was of 517 ± 314 cells/mm3 (range 5-1,305) and 
HIV-RNA copies/ml of 58,183  ±  151,553 (range 19-
875, 716).
By the comparison of the MN frequency in peripheral 
blood mononuclear cells (PBMC), a significant differ-
ence between HIV patients (15.5  ±  9.8) and controls 
(6.0 ± 3.6) (p < 0.001) was revealed (Fig. 1). Table  II 
shows the results of the univariate and multivariate lin-
ear regression analyses, demonstrating the relationships 
between MN and other variables. Two risk factors were 
strongly associated with increased MN frequency in 
HIV patients upon univariate analysis: HCV infection 
(r = 0.31; p < 0.001) and HIV-RNA (r = 0.29; p < 0.05). 
However, only VL significantly correlates (r  =  0.29; 
p < 0.05) with the MN frequency in a multiple regression 
model, where variables with p value < 0.05 in the uni-
variate analysis were included as independent (Tab. II).
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Discussion
The aim of this study was to evaluate the cytogenetic 
damage in PBMC of HIV patients, considering that 
DNA damage may develop ADMs and NADMs.
To this end, two groups have been enrolled: HIV patients 
undergoing ART treatment (study group) and subjects 
with no HIV-infection (control group). The HIV group 
included many recently diagnosed patients, which ben-
efited from ART therapy for a limited time, with virus 
not yet suppressed. All the patients started therapy at the 
time of diagnosis. 
The initial design of the study included a third group of 
HIV-infected subjects that did not receive therapy (naïve 
group). Anyhow, over the course of the study, very few 
new cases of HIV occurred. Therefore, it was not possi-
ble to select a sufficient sample size to make statistically 
significant comparison. The absence of a naïve group is 
a major weakness of this study because it has not al-
lowed the dissociation of the damages induced by the 
infection and those induced by the therapy.
The introduction of ART has modified the natural his-
tory of HIV infection, leading to an increase of survival 
time and a reduced AIDS-related mortality, but also to 
an excess of neoplastic diseases that have becoming 
one of the most common cause of death among HIV pa-
tients [28, 29]. The treatment leads to viral suppression 
but does not completely restore the immune damage, so 
ineffective immune response could be the reason why 
HIV patients have an increased risk of developing dif-
ferent types of tumours [30, 31]. The role of HIV in the 
development of neoplastic pathologies can be linked to 
severe immunodeficiency with consequent impairment 
of immunological surveillance against infectious agents 
(with predisposition to the appearance of virus-associ-
ated tumours) and the cells with malignant transforma-
tion [32-34], although its role in the process of carcino-
genesis has not yet been completely clarified. 
Our study provides evidence that HIV infection may 
have an impact on the genetic damage. Indeed, MN fre-
quency was significantly increased in the study group 
compared to the control group. 
Our findings are in line with those of Lima and col-
leagues that show an increase in the frequency of multi-
ple MN in oral mucosa cells in HIV patients compared 
to healthy controls [35]. 
The micronucleus cytome assay applied in buccal exfo-
liated cells is a complementary method for measuring 
DNA damage and cytotoxic effects caused by exposure 
to genotoxic agents, impact of nutrition, lifestyle factors 
and virus [25, 36]. 
Several studies, reporting the parallel application of the 
MN test in both PBMC and in buccal cells, have shown 
a positive correlation between the MN frequencies in 
the two surrogate tissues [37, 38], therefore the results 
of the two methods can be comparable. In addition, the 
strong correlation of MN frequency in buccal exfoliated 
cells with that in PBMC, implies that systemic genotoxic 
effects may also impact on and be detectable in buccal 
cells. Hence, the possible human health risks associ-
ated with high MN frequency in both tissues may also 
be comparable, including the association with cancer 
risk [24].
We have also analysed the association among the fre-
quency of MN with baseline HIV-specific clinical vari-
ables and patient characteristics. The univariate analysis 
has showed a statistical significance with HCV infection 
and HIV-RNA, while the multivariate analysis has dis-
played significant association only between HIV-RNA 
and frequency of MN. The 54% of HIV-infected patients 
Tab. I. Demographic, clinical characteristics and laboratory values of 
patient’s HIV and control group.
HIV-1+
(n = 52)
Control
(n = 55)
P-value
Age, years 
(mean ± SD)
42.5 ± 9.6 42.6 ± 9.9 0.9658°
Gender, male, 
n (%)
40 (76.9) 42 (76.4) 0.8727^
Obesity, 
n (%)
1 (1.9) 1 (1.8) 1.000#
Smoke use, 
n (%)
25 (48.1) 17 (30.9) 0.1053^
HCV infection, 
n (%)
18 (34.6) 0 (0.0) < 0.0001#
Diabetes, 
n (%)
1 (1.9) 1 (1.8) 1.000#
Mode of transmission
• Heterosexual 
contact, n (%)
19 (36.5) -
• Male-to-
male sexual 
contact, n (%)
21 (40.4)
• Injection dug 
use, n (%)
11 (21.2) -
• Other, n (%) 1 (1.9) -
Duration HIV 
infection, 
months
95 
(1-339)
-
Duration HIV 
infection > 36 
months, n (%)
33  (63.5) -
AIDS, 
n (%)
2 (3.8) -
HIV RNA
(mean ± SD)*
126,042 ± 82,553 -
Undetectable 
HIV viral load, 
n (%)
28 (53.8) -
CD4 cells/mm3, 
mean ± SD 
(range)
517 ± 314 
(5-1305)
-
Nadir CD4 cells/
mm3, mean ± SD 
(range)
233 ± 166 
(2-755)
-
Duration of ART, 
months
61.1 
(1-203)
Duration of ART 
> 36 months, 
n (%)
30  (57.7)
°: Independent samples t-test; ^: Chi-square test; #: Fisher’s exact test; 
*: mean of viremic patients.
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enrolled, all in therapy with ART, were aviremic (with 
VL < 20 copies/ml). In these patients, the mean number 
of MN (13.2 ± 6.5) was significantly lower (p < 0.002) 
than in patients with uncontrolled viremia (17.8 ± 12.4). 
These data support the hypothesis that viremia plays a de-
terminant role in the induction of chromosomal damage. 
The current knowledge of genotoxic effects of infec-
tion and therapy are still limited. Only few studies have 
tried to explain the MN formation. Shimura M et al. and 
Tachiwana H et al. have linked this process to the action 
of the accessory gene Vpr of HIV, which induces dou-
ble-strand breaks of chromosomal DNA [21, 22], while 
Lourenco ED and colleagues justify it with a clastogenic 
(chromosome breakage) and aneugenic (chromosome 
loss) action of the therapy [39].
Our work supports the hypothesis of cytogenetic dam-
age induced by HIV infection, but further studies in na-
ïve and in ART therapy patients and with different thera-
peutic programmes, are mandatory. 
Moreover, our data show that exposure to the virus plays 
a key role in the development of cytogenetic damage, 
although the precise exposure date is not known. Finally, 
many questions regarding the relationship between HIV 
and AIDS related and non-AIDS related cancer are still 
left unanswered. 
Future researches should be focused on identifying early 
and sensitive risk indicators for the development of cancer.
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